On May 16, 2019 Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, reported that it will present a poster at the 2019 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) meeting, which is being held from May 31 to June 4, 2019, at the McCormick Place Convention Center in Chicago, Illinois (Press release, Fusion Pharmaceuticals, MAY 16, 2019, View Source [SID1234536410]). The abstract is available on the ASCO (Free ASCO Whitepaper) meeting website at View Source
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Company will present a poster highlighting a Phase 1 study evaluating its lead candidate [225Ac]-FPI-1434, a radioimmunoconjugate consisting of a humanized monoclonal antibody that binds to the external domain of IGF-1R, a bifunctional chelate, proprietary linker, and the alpha-emitting radionuclide actinium-225 (Ac-225). The indium-111 analog, [111In]-FPI-1547, which contains the identical antibody and bifunctional chelate is used for patient selection and quantification of IGF-1R expressing targets prior to therapy.
The Phase 1 study has a primary objective of evaluating the safety and tolerability of [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection in patients with advanced refractory solid tumors and to determine the maximum tolerated dose of a single [225Ac]-FPI-1434 Injection. The study is currently enrolling patients in Canada.
Details of the poster presentation are below:
Abstract Title: A Phase I study of [225Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors.
Abstract Number for Publication: TPS3152
Session Title: Developmental Therapeutics and Tumor Biology (Nonimmuno)
Date: Saturday, June 1, 2019, 8:00 AM-11:00 AM CDT
Location: McCormick Place, Hall A